How have DMAC and EOLS total returns compared?

Over the past 5 years, DMAC delivered 16.41% and EOLS delivered 0.46% annualized total return. Past performance doesn't predict future results.

DiaMedica Therapeutics Inc. (DMAC) vs Evolus, Inc. (EOLS)

A side-by-side comparison of DiaMedica Therapeutics Inc. and Evolus, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

DMAC

DiaMedica Therapeutics Inc.

$449M

$8.33HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT

EOLS

Evolus, Inc.

$489M

$7.43HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT

Total return — DMAC vs EOLS

growth of $100 · dividends reinvested · last 9y

DMAC +68.4% (+6.0%/yr)EOLS -35.0% (-4.7%/yr)DMAC compounded faster over this window

DMAC EOLS

DMAC vs EOLS: by the numbers

•EOLS is the larger company ($489M vs $449M market cap).
•Both run net losses; DMAC's is the smaller (0.00% vs -10.85% net margin).

Metrics side by side

Valuation

Metric	DMAC	EOLS
P/S ratio	N/A	1.54
P/B ratio	11.71	N/A

Profitability

Metric	DMAC	EOLS
Gross margin	0.00%	66.25%
Operating margin	0.00%	-7.33%
Net margin	0.00%	-10.85%
ROE	-97.92%	N/A
ROIC	-100.87%	-15.54%

Growth (annualized)

Metric	DMAC	EOLS
Revenue CAGR (5Y)	N/A	32.82%
Total return CAGR (5Y)	16.41%	0.46%

Frequently asked

How have DMAC and EOLS total returns compared?: Over the past 5 years, DMAC delivered 16.41% and EOLS delivered 0.46% annualized total return. Past performance doesn't predict future results.

Go deeper

Full DMAC analysis Full EOLS analysis Interactive comparison tool

Dig into the metrics

DiaMedica Therapeutics ROE Evolus ROE DiaMedica Therapeutics operating margin Evolus operating margin DiaMedica Therapeutics revenue growth Evolus revenue growth DiaMedica Therapeutics free cash flow Evolus free cash flow

DiaMedica Therapeutics & Evolus appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.